Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2969312 | 0.79 | MMP9 (0.35) | MMP9MMP8 | |
| SCHEMBL15228983 | 0.79 | MMP9 (0.35) | MMP9MMP8 | |
| SCHEMBL20528108 | 0.78 | MMP9 (0.34) | MMP9MMP8 | |
| SCHEMBL20528106 | 0.78 | MMP9 (0.34) | MMP9MMP8 | |
| SCHEMBL12505758 | 0.78 | MMP9 (0.34) | MMP9MMP8 | |
| SCHEMBL14780355 | 0.78 | CTSK (0.42) | — | |
| SCHEMBL319703 | 0.73 | SLC1A3 (0.32) | — | |
| SCHEMBL12505764 | 0.73 | SLC1A3 (0.32) | — | |
| SCHEMBL15132449 | 0.72 | MMP9 (0.58) | MMP9MMP8 | |
| SCHEMBL16761492 | 0.70 | ALDH1A1 (0.32) | MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190289-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-25 | — | — | US | disclosed |
| EP-2585447-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012006055-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190289-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | SLC10A1, ACE, CEL | MMP9 771/4885MMP8 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.